Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A therapeutic peptide vaccine targeting hypoxia-inducible factor 1-alpha (HIF-1α) and the hepatocyte growth factor receptor (c-MET). HIF-1α is a transcription factor that regulates the cellular response to hypoxia and is frequently upregulated in chemoresistant tumors, while c-MET is a receptor tyrosine kinase that promotes tumor cell proliferation, survival, and metastasis. The vaccine is designed to elicit a type I immune response, increasing the infiltration of CD8+ T cells and improving the M1/M2 macrophage ratio within the tumor microenvironment. Preclinical studies in models of high-grade serous ovarian carcinoma indicate that this vaccine can reverse hypoxia-induced signaling and reprogram the immune environment to overcome platinum resistance, particularly when used in combination with carboplatin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypoxia-inducible factor 1-alpha peptide vaccine + hepatocyte growth factor receptor peptide vaccine.